US pharma giant Merck & Co has applied to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its oral antiviral drug molnupiravir, developed together with Ridgeback Biotherapeutics. The New Jersey-based pharma and the Florida-headquartered biotech are positioning the pill as a preventative therapy, rather than as a therapeutic, the latter a path other industry heavyweights are taking.
